Cognition Therapeutics' Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer's Patients
CGTXCognition Therapeutics(CGTX) GlobeNewswire News Room·2024-07-29 19:00
  • CT1812 Treatment Showed ~40% Mean Improvement in Cognitive Measures vs Placebo -- Consistent Positive Changes Across Cognitive and Functional Measures -- Favorable Safety Profile with Most Treatment-Related Adverse Events Mild or Moderate -- Significant Changes in Neurofilament Light Chain, a Marker of Neurodegeneration -- Investor Webcast to be Conducted at 8:30a.m. ET to Review Findings - PURCHASE, N.Y., July 29, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDA ...